Laurie Fisher, MD
Family Medicine · Overland Park, KSNPI 1831184902
Payments from drug & device makers
Across 237 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$337
- Amgen$313
- Pfizer$292
- Novo Nordisk$257
- Takeda Pharmaceuticals U.S.A., Inc.$138
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,431100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,001 |
| Lilly USA, LLC | 23 | $337 |
| Amgen | 18 | $313 |
| Pfizer | 31 | $292 |
| Novo Nordisk | 19 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $138 |
| Corium, LLC | 6 | $112 |
| AstraZeneca | 9 | $111 |
| Axsome Therapeutics, Inc. | 4 | $97 |
| Antares Pharma, Inc. | 5 | $83 |
| Merck | 6 | $77 |
| Boehringer Ingelheim | 4 | $67 |
| GSK | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $47 |
| Johnson & Johnson | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Exact Sciences | 2 | $37 |
| Shire North American Group Inc | 3 | $36 |
| Ironwood Pharmaceuticals, Inc | 3 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $27 |
| Ardelyx, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Coopersurgical, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
How this compares
$3,440 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $107,781 |
| OzempicSemaglutide | 32 | $69,281 |
| EliquisApixaban | 44 | $51,549 |
| XareltoRivaroxaban | 40 | $30,611 |
| JardianceEmpagliflozin | 20 | $30,174 |
| FarxigaDapagliflozin Propanediol | 24 | $29,040 |
| LinzessLinaclotide | 24 | $24,414 |
| RybelsusSemaglutide | 11 | $21,917 |
| TrulicityDulaglutide | 11 | $20,940 |
| EntrestoSacubitril/Valsartan | 30 | $20,659 |
| Morphine Sulfate ErMorphine Sulfate | 89 | $9,663 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 200 | $8,194 |
| Fentanyl | 30 | $7,719 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $5,650 |
| Duloxetine Hcl | 99 | $5,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $337 | $128,72178 claims |
| Novo NordiskOzempic, Rybelsus | $257 | $91,19843 claims |
| PfizerEliquis | $292 | $51,54944 claims |
| Johnson & JohnsonXarelto | $45 | $30,61140 claims |
| Boehringer IngelheimJardiance | $67 | $30,17420 claims |
| AstraZenecaFarxiga | $111 | $29,04024 claims |
| AbbVieLinzess, Synthroid | $1,001 | $26,22462 claims |
| NovartisEntresto | $13 | $20,65930 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $13 | $1,22424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Overland Park
- Maranda NguyenOverland Park$151K
- Trystan CrookOverland Park$15K
- Liliana NazarioOverland Park$15K
- Staci JordanOverland Park$14K
- Neal EricksonOverland Park$13K
- John HansenOverland Park$13K
- David DobratzOverland Park$13K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.